AXP Share Price

Open 115.05 Change Price %
High 115.05 1 Day -0.95 -0.82
Low 115.05 1 Week -3.45 -2.91
Close 115.05 1 Month 2.35 2.09
Volume 13 1 Year -59.30 -34.01
52 Week High 175.50
52 Week Low 102.00
AXP Important Levels
Resistance 2 115.05
Resistance 1 115.05
Pivot 115.05
Support 1 115.05
Support 2 115.05
ETR Germany Most Active Stocks
CBK 7.27 3.56%
CBK 7.27 3.56%
DBK 17.44 5.76%
DBK 17.44 5.76%
EOAN 6.46 0.31%
EOAN 6.46 0.31%
DTE 15.29 1.53%
DTE 15.29 1.53%
DTE 15.29 1.53%
DTE 15.29 1.53%
More..
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
VG8 6.30 21.15%
BCY2 10.91 16.93%
5M71 39.00 13.70%
CUR 1.09 13.54%
CUR 1.09 13.54%
CUR 1.09 13.54%
I7N 0.52 13.04%
BPG 0.33 10.00%
BPG 0.33 10.00%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
M6YA 0.84 -60.00%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
E8X 0.25 -32.43%
GRF 0.80 -9.09%
GRF 0.80 -9.09%
GRF 0.80 -9.09%
More..

Alexion Pharmaceuticals Inc (ETR: AXP)

AXP Technical Analysis 2
As on 7th Dec 2016 AXP Share Price closed @ 115.05 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 145.37 & Buy for SHORT-TERM with Stoploss of 113.14 we also expect STOCK to react on Following IMPORTANT LEVELS.
AXP Target for December
1st Target up-side 130.68
2nd Target up-side 139.22
3rd Target up-side 147.76
1st Target down-side 106.32
2nd Target down-side 97.78
3rd Target down-side 89.24
AXP Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.alexionpharm.com
AXP Address
AXP
352 Knotter Drive
Cheshire, CT 06410
United States
Phone: 203-272-2596
Fax: 203-271-8198
AXP Latest News
Interactive Technical Analysis Chart Alexion Pharmaceuticals Inc ( AXP ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Alexion Pharmaceuticals Inc
AXP Business Profile
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. It offers Soliris (eculizumab), a therapeutic product to treat paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. The company also conducts Phase IV clinical trials on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trials for its usage for the treatment of PNH pediatric trial, presensitized renal transplant, delayed kidney transplant graft function, hemolytic uremic syndrome, neuromyelitis optica, myasthenia gravis, and cold agglutinin disease. In addition, it develops Asfotase alfa that is under Phase II clinical trial for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; ALXN 1007, a novel humanized antibody for treating inflammatory disorders; and cPMP that is in Phase I trial for treating metabolic disorders. The company primarily serves distributors, pharmacies, hospitals, hospital buying groups, and other health care providers, as well as governments and government agencies. Alexion Pharmaceuticals, Inc. has a strategic agreement with Moderna Therapeutics, Inc. for the development of messenger RNA therapeutics to treat rare diseases. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.